Key facts
- Amplified Sciences’s last known valuation is $9.0M (Dec 2023).
- It has raised $11.2M across 3 recorded rounds; the latest was Seed Round ($3.0M) in Aug 2025.
- Notable investors include Plug and Play Tech Center, US National Science Foundation, MedTech Innovator, National Institutes of Health, Keiretsu Forum — 32 tracked in total.
- Amplified Sciences has filed 6 Form Ds with the SEC since 2020, most recently Feb 2026 ($3.0M sold to 41 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 32 names
- ·Watchlist + deal alerts for Amplified Sciences
Funding rounds
3 roundsAbout Amplified Sciences
Developer of a diagnostic test platform designed for the detection of debilitating diseases across oncology and chronic kidney disease. The company's platform offers a sensitive optical reporter system integrated with machine learning and multi-analyte assays, which helps to detect biomarker levels and activity in minute volumes of pancreatic cyst fluid for patients at risk for pancreatic cancer diagnosed with pancreatic cystic lesions, enabling clinicians focused on the detection of diseases like pancreatic cancer to improve outcomes and reduce unnecessary procedures.
- Sector
- Healthcare
- HQ
- West Lafayatte, IN, United States
- Founded
- 2016
- Employees
- 7
- Website
- amplifiedsciences.com/
- Ownership
- Privately Held (backing)
Amplified Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amplified Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amplified Sciences in its N-PORT filings yet. We sweep new filings monthly.